TOP STORIES

• TRENDS Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
  June 20, 2018

• REGULATORY PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
  June 19, 2018

• ORGANIZATION Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
  June 18, 2018

• REGULATORY Authorized Generics for Aimix, Cravit IV Join NHI Price List
  June 15, 2018

• REGULATORY Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
  June 14, 2018

• REGULATORY Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
  June 14, 2018

• REGULATORY Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
  June 13, 2018

• REGULATORY PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
  June 13, 2018

• BUSINESS Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
  June 12, 2018

• REGULATORY MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
  June 11, 2018

• BUSINESS Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
  June 8, 2018

• REGULATORY AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
  June 7, 2018

• REGULATORY Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
  June 6, 2018

• ACADEMIA MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
  June 5, 2018

• BUSINESS FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
  June 5, 2018

• BUSINESS FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
  June 4, 2018

• BUSINESS Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
  June 1, 2018

• TRENDS Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
  May 31, 2018

• REGULATORY Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
  May 30, 2018

• BUSINESS Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
  May 29, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• 147
• …
• Next ›
• 最終 »